THA—A Review of the Literature and Its Use in Treatment of Five Overdose Patients

Summers, William K.; Kaufman, Kenneth R.; Altman, F. D.; Fischer, John Martin

doi:10.3109/15563658008989949

Cited by 61 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Summers ctal. [82] used THA in preference to physostigmine in cases of tri cyclic overdose, due to its milder peripheral side effects, and suggested its potential for alleviating symptoms of dementia. Clinical trials of THA followed with some enthusiasm.…”

Section: Tetraliydroami Noacridinementioning

confidence: 99%

The Cholinergic Model of Dementia, Alzheimer Type: Progression from the Unitary Transmitter Concept

Holttum¹,

Gershon²

1992

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Efforts continue toward the goal of uncovering a dominant pathogenetic and therapeutic model for Alzheimer type dementia. This article critically reviews the evolution and current status of unitary transmitter concepts, the prototype of which is the cholinergic model proposed by Deutsch and others, from early animal studies to ongoing drug trials. We conclude that evidence is sufficient to dismiss such models as a means of directing treatment and further resources. A survey of novel approaches to Alzheimer type dementia, many of which transcend unitary thought, reveals a more promising direction for further research.

show abstract

Section: Tetraliydroami Noacridinementioning

confidence: 99%

The Cholinergic Model of Dementia, Alzheimer Type: Progression from the Unitary Transmitter Concept

Holttum¹,

Gershon²

1992

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…has potent anticholinesterase activity [1]. It has been used for the treatment of central anticholinergic syndrome caused by drug overdose [2,3], intractable pain from terminal carcinoma [4], myasthenia gravis [5], and as a decurarizing agent [6]. Renewed interest in THA has been generated by its ef®cacy as therapy for memory loss [7], being the ®rst drug approved by the U.S. Food and Drug Administration for the treatment of patients with Alzheimer's disease.…”

Section: Introductionmentioning

confidence: 99%

Electrochemical Characterization of Tacrine, an Antialzheimer's Disease Drug, and Its Determination in Pharmaceuticals

et al. 2000

View full text Add to dashboard Cite

Tacrine, 9-amino-1,2,3,4-tetrahydroacridine, an antialzheimer's disease agent was electrochemically studied and a polarographic method for its quantitative determination in pharmaceuticals was developed. Tacrine was electrochemically reduced and oxidized in aqueous medium, but for analytical purposes the cathodic behavior was prefered. According to the linear relation between the peak current and the tacrine concentration a differential pulse polarographic method was developed. Precision and accuracy of the developed method was checked by recovery studies. The proposed method was applied to the individual capsule assay (ICA) of the commercial capsules, showing that the uniformity content requirements were ful®lled. Alternatively a UV spectroscopic characterization was conducted, from the pH dependence of the absorbance bands an apparent pK a of 10.44 was obtained. For comparative purposes a spectrophotometric determination also was developed.

show abstract

“…3.1.1.7, AChE) such as organophosphates (4,5). One of the acetylcholinesterase inhibitors is tetrahydroaminoacridine (tacrine), which is a reversible inhibitor with a long-lasting effect on the central nervous system (6).…”

Section: Introductionmentioning

confidence: 99%

Sensitivity of bovine retinal acetylcholinesterase (E.C. 3.1.1.7) toward tacrine: Kinetic characterization

Al‐Jafari

Kamal

Alhomida

1998

J. Biochem. Mol. Toxicol.

View full text Add to dashboard Cite

THA—A Review of the Literature and Its Use in Treatment of Five Overdose Patients

Cited by 61 publications

References 37 publications

The Cholinergic Model of Dementia, Alzheimer Type: Progression from the Unitary Transmitter Concept

The Cholinergic Model of Dementia, Alzheimer Type: Progression from the Unitary Transmitter Concept

Electrochemical Characterization of Tacrine, an Antialzheimer's Disease Drug, and Its Determination in Pharmaceuticals

Sensitivity of bovine retinal acetylcholinesterase (E.C. 3.1.1.7) toward tacrine: Kinetic characterization

Contact Info

Product

Resources

About